Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...
HEDGE MAZE, TWINS, TYPEWRITER Connections grids vary widely and change every day. If you couldn’t solve today’s puzzle, be sure to check back in tomorrow. Wyna Liu, who has been editing ...